Louisiana State Employees Retirement System Invests $2.08 Million in Ralliant Corporation $RAL

Louisiana State Employees Retirement System purchased a new stake in Ralliant Corporation (NYSE:RAL) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $2,080,000.

Other institutional investors have also recently made changes to their positions in the company. Danske Bank A S purchased a new position in Ralliant during the fourth quarter worth about $25,000. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant in the 4th quarter valued at about $26,000. Allworth Financial LP boosted its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares during the last quarter. Palisade Asset Management LLC purchased a new position in shares of Ralliant during the third quarter worth about $26,000. Finally, BOKF NA purchased a new position in shares of Ralliant during the third quarter worth about $29,000.

Ralliant Price Performance

Shares of Ralliant stock opened at $73.72 on Wednesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The business’s 50 day simple moving average is $59.20 and its two-hundred day simple moving average is $51.56. The stock has a market capitalization of $8.25 billion and a P/E ratio of -6.74. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million during the quarter. Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts forecast that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Oppenheimer lifted their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. TD Cowen raised their price objective on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Evercore started coverage on shares of Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Finally, Royal Bank Of Canada increased their target price on Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research note on Wednesday, May 13th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $69.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.